CD8A and cancer: revealed in cancer models receiving ICIs therapy that IL-6R inhibition alleviates ICI-related toxicity by reducing Th17 differentiation, pro-inflammatory cytokine secretion, and neutrophil chemokine production, while simultaneously enhancing tumor immunity by increasing Th1 and CD8+ T effector cells (32).